Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

卷:60

Article

Ho, Jennifer E.^1,2,3  Liu, Chunyu¹  Lyass, Asya^1,4  Courchesne, Paul¹  Pencina, Michael J.^1,4  Vasan, Ramachandran S.^1,5,6  Larson, Martin G.^1,4  Levy, Daniel^1,2 

[1] NHLBI, Framingham Heart Study, Framingham, MA 01702 USA

[2] NHLBI, Ctr Populat Studies, Bethesda, MD 20892 USA

[3] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA

[4] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA

[5] Boston Univ, Sch Med, Cardiol Sect, Boston, MA 02118 USA

[6] Boston Univ, Sch Med, Dept Prevent Med & Epidemiol, Boston, MA 02118 USA

关键词: biomarker;    epidemiology;    heart failure;    prognosis;   

DOI  :  10.1016/j.jacc.2012.04.053

来源: Elsevier

【 摘 要 】

Objectives The aim of this study was to examine the relation of galectin-3 (Gal-3), a marker of cardiac fibrosis, with incident heart failure (HF) in the community. Background Gal-3 is an emerging prognostic biomarker in HF, and experimental studies suggest that Gal-3 is an important mediator of cardiac fibrosis. Whether elevated Gal-3 concentrations precede the development of HF is unknown. Methods Gal-3 concentrations were measured in 3,353 participants in the Framingham Offspring Cohort (mean age 59 years; 53% women). The relation of Gal-3 to incident HF was assessed using proportional hazards regression. Results Gal-3 was associated with increased left ventricular mass in age-adjusted and sex-adjusted analyses (p = 0.001); this association was attenuated in multivariate analyses (p = 0.06). A total of 166 participants developed incident HF and 468 died during a mean follow-up period of 11.2 years. Gal-3 was associated with risk for incident HF (hazard ratio [HR]: 1.28 per 1 SD increase in log Gal-3; 95% confidence interval [CI]: 1.14 to 1.43; p < 0.0001) and remained significant after adjustment for clinical variables and B-type natriuretic peptide (HR: 1.23; 95% CI: 1.04 to 1.47; p = 0.02). Gal-3 was also associated with risk for all-cause mortality (multivariable-adjusted HR: 1.15; 95% CI: 1.04 to 1.28; p = 0.01). The addition of Gal-3 to clinical factors resulted in negligible changes to the C-statistic and minor improvements in net reclassification improvement. Conclusions Higher concentration of Gal-3, a marker of cardiac fibrosis, is associated with increased risk for incident HF and mortality. Future studies evaluating the role of Gal-3 in cardiac remodeling may provide further insights into the role of Gal-3 in the pathophysiology of HF. (J Am Coll Cardiol 2012;60:1249-56) (C) 2012 by the American College of Cardiology Foundation

【 授权许可】

Free